Putting people with Fabry first: a talent that Amicus Therapeutics and FIN share. This commonality has ensured a strong partnership, spanning more than 16 years. Amicus Therapeutics is a pharma industry leader advancing the professional field of patient advocacy; it develops and delivers medicine for people living with rare diseases. Jayne C. Gershkowitz, Chief [...]
Fabry disease is rather easy to test for and diagnose, yet there continues to be limited awareness about the disease. Fabry Australia, a FIN member , is on a quest to place it on the national agenda. Sheridan Campbell explains how her organisation raises awareness. Challenges Oftentimes people exhibit symptoms for many years, without [...]
Save the Date Fabry Expert Meeting 2023 - April 21-23, 2023
Rare Diseases International Annual Membership Meeting
Fabry community leadership in an evolving landscape
Freeline will be progressing to the second dose cohort in the MARVEL-1 study immediately with first patient dosing expected in mid-2022
International Fabry Congress MPS Lysosomales Association Spain
Help us to train Face2Gene to diagnose Fabry patients earlier!
